|
|
 Previous Article | Table of Contents | Next Article 
Pyruvate kinase synthesis and degradation by normal and pathologic cells
during erythroid maturation
I Max-Audit, D Kechemir, MT Mitjavila, W Vainchenker, D Rotten and R Rosa
INSERM U91 Hopital Henri Mondor, Creteil, France.
Mature erythrocytes contain a specific isozyme of pyruvate kinase (R- PK)
while immature erythroblasts coexpress R-PK and another isozyme, M2- PK. To
determine what roles degradation and decreasing of synthesis played in the
disappearance of M2-PK during erythroid maturation, M2-PK and R-PK
synthesis and degradation were studied in erythroblasts from fetal liver
and blood BFU-E-derived erythroblasts from healthy subjects, an
erythroleukemic patient, and a patient with an erythrocyte PK hyperactivity
associated with M2-PK persistence in mature erythrocytes. In normal
erythroblasts, R-PK synthesis was constant throughout erythroid maturation,
whereas M2-PK synthesis decreased to the point of becoming undetectable.
R-PK degradation was very low, while M2-PK degradation was more pronounced
and steady during erythroid maturation. In leukemic erythroblasts, total
protein turnover was higher than in normal cells, but the M2-PK degradation
rate was lower. In erythroblasts from the patient with M2-PK persistence in
mature erythrocytes, M2-PK synthesis did not decline with cell maturation.
In conclusion, our results emphasize the importance of the decrease of M2-
PK synthesis in the disappearance of M2-PK during erythroid maturation.
Further studies of patients with pathologic persistence of M2-PK synthesis
will help in the understanding of this event involved in erythroid
maturation.
Volume 72,
Issue 3,
pp. 1039-1044,
09/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Kanno, T. Utsugisawa, S. Aizawa, T. Koizumi, K.-i. Aisaki, T. Hamada, H. Ogura, and H. Fujii
Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase deficiency
Haematologica,
June 1, 2007;
92(6):
731 - 737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. van Wijk and W. W. van Solinge
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
Blood,
December 15, 2005;
106(13):
4034 - 4042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Diez, F. Gilsanz, J. Martinez, S. Perez-Benavente, N. W. Meza, and J. M. Bautista
Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression
Blood,
September 1, 2005;
106(5):
1851 - 1856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tsujino, H. Kanno, K. Hashimoto, H. Fujii, T. Jippo, E. Morii, Y.-M. Lee, H. Asai, S. Miwa, and Y. Kitamura
Delayed Onset of Hemolytic Anemia in CBA-Pk-1slc/Pk-1slc Mice With a Point Mutation of the Gene Encoding Red Blood Cell Type Pyruvate Kinase
Blood,
March 15, 1998;
91(6):
2169 - 2174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
